Is there any association between insulin resistance and thyroid cancer?: A case control study

Endocrine

Volumn 45, Issue 1, 2014, Pages 55-60

  Balkan, Fevzi ^a   Onal, Eda Demir ^a   Usluogullari, Alper ^a   Tuzun, Dilek ^a   Ozdemir, Didem ^a   Inancli, Serap Soytac ^a   Ersoy, Reyhan ^a   Cakir, Bekir ^a  

^a YILDIRIM BEYAZIT UNIVERSITY   (Turkey)

Author keywords

Diabetes mellitus; Dyslipidemia; Hypertension; Insulin resistance; Obesity; Thyroid neoplasms

Indexed keywords

GLUCOSE; INSULIN;

ADULT; ARTICLE; BODY MASS; CASE CONTROL STUDY; CONTROLLED STUDY; DIET RESTRICTION; DISEASE ASSOCIATION; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MIDDLE AGED; OUTCOME ASSESSMENT; PREVALENCE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SCORING SYSTEM; THYROID CANCER; TUMOR VOLUME; UTERINE CERVIX CARCINOMA;

ADOLESCENT; ADULT; AGED; CASE-CONTROL STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPERPLASIA; INSULIN RESISTANCE; MALE; METABOLIC SYNDROME X; MIDDLE AGED; RISK FACTORS; THYROID GLAND; THYROID NEOPLASMS; THYROID NODULE; YOUNG ADULT;

EID: 84895902424     PISSN: 1355008X     EISSN: 15590100     Source Type: Journal    
DOI: 10.1007/s12020-013-9942-x     Document Type: Article

References (33)

1. G.M. Reaven, Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 37, 1595-1607 (1988)
2. G. Hu, Q. Qiao, J. Tuomilehto, The metabolic syndrome and cardiovascular risk. Curr. Diabetes Rev. 1, 137-143 (2005)
3. R.L. Ahmed, K.H. Schmitz, K.E. Anderson, W.D. Rosamond, A.R. Folsom, The metabolic syndrome and risk of incident colorectal cancer. Cancer 107, 28-36 (2006)
4. L. Lund Haheim, T.F. Wisloff, I. Holme, P. Nafstad, Metabolic syndrome predicts prostate cancer in a cohort of middleaged Norwegian men followed for 27 years. Am. J. Epidemiol. 164, 769-774 (2006)
5. W.G. Nelson, A.M. De Marzo, T.L. DeWeese, W.B. Isaacs, The role of infl ammation in the pathogenesis of prostate cancer. J. Urol. 172, 6-11 (2004)
6. R. Kaaks, A. Lukanova, B. Sommersberg, Plasma androgens, IGF-1, body size, and prostate cancer risk: a synthetic review. Prostate Cancer Prostatic Dis. 3, 157-172 (2000)
7. E.A. Platz, A.M. De Marzo, Epidemiology of infl ammation and prostate cancer. J. Urol. 171, 36-40 (2004)
8. B.A. Kilfoy, S.S. Devesa, M.H. Ward, Y. Zhang, P.S. Rosenberg, T.R. Holford, W.F. Anderson, Gender is an age-specific effect modifier for papillary cancers of the thyroid gland. Cancer Epidemiol. Biomarkers Prev. 18, 1092-1100 (2009)
9. B.A. Kilfoy, T. Zheng, T.R. Holford, X. Han, M.H. Ward, A. Sjodin, Y. Zhang, Bai, C. Zhu, G.L. Guo, N. Rothman, Y. Zhang, International patterns and trends in thyroid cancer incidence, 1973-2002. Cancer Causes Control 20, 525-531 (2009)
10. L. Pagano, M. Caputo, M.T. Samà, V. Garbaccio, M. Zavattaro, M.G. Mauri, F. Prodam, P. Marzullo, R. Boldorini, G. Valente, G. Aimaretti, Clinical-pathological changes in differentiated thyroid cancer (DTC) over time (1997-2010): data from the University Hospital "Maggiore della Carità" in Novara. Endocrine 42, 382-390 (2012)
11. F. Pacini, Changing natural history of differentiated thyroid cancer. Endocrine 42, 229-230 (2012)
12. J. Rezzonico, M. Rezzonico, E. Pusiol, F. Pitoia, H. Niepomniszcze, Introducing the thyroid gland as another victim of the insülin resistance syndrome. Thyroid 18, 461-464 (2008)
13. S. Ayturk, A. Gursoy, A. Kut, C. Anil, A. Nar, N.B. Tutuncu, Metabolic syndrome and its components are associated with increased thyroid volume and nodule prevalence in a mild-to-moderate iodine-deficient area. Eur. J. Endocrinol. 161, 599-605 (2009)
14. J.N. Rezzónico, M. Rezzónico, E. Pusiol, F. Pitoia, H. Niepomniszcze, Increased prevalence of insulin resistance in patients with differentiated thyroid carcinoma. Metab. Syndr. Relat. Disord. 7, 375-380 (2009)
15. Arslan M.; Atmaca A.; Ayvaz G.; Başkal N.; Beyhan Z.; Bolu E.; Can S.; CorakcI A. et al.: Metabolik Sendrom KIlavuzu. Türkiye Endokrinoloji ve Metabolizma HastalIklarI Derneǧi, Metabolik Sendrom ÇalIşma Grubu. Metrix matbaacIlIk, İstanbul (2007)
16. J. Brunn, U. Block, G. Ruf, I. Bos, W.P. Kunze, P.C. Scriba, Volumetric analysis of thyroid lobes by real-time ultrasound. Dtsch. Med. Wochenschr. 106, 1338-1340 (1981)
17. D.R. Matthews, J.P. Hosker, A.S. Rudenski, B.A. Naylor, D.F. Treacher, R.C. Turner, Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28, 412-419 (1985)
18. D.R. Clemmons, Structural and functional analysis of insulin-like growth factors. Br. Med. Bull. 45, 465-480 (1989)
19. R. Paramesweran, S. Brooks, G.P. Sadler, Molecular pathogenesis of follicular cell derived thyroid cancers. Int. J. Surg. 8, 186-193 (2010)
20. T. Stocks, K. Rapp, T. Bjørge, J. Manjer, H. Ulmer, R. Selmer, A. Lukanova, D. Johansen, H. Concin, S. Tretli, G. Hallmans, H. Jonsson, P. Stattin, Blood glucose and risk of incident and fatal cancer in the metabolic syndrome and cancer Project (me-can): analysis of six prospective cohorts. PLoS Med. 6, e1000201 (2009)
21. B. Aschebrook-Kilfoy, M.M. Sabra, A. Brenner, S.C. Moore, E. Ron, A. Schatzkin, A. Hollenbeck, M.H. Ward, Diabetes and thyroid cancer risk in the National Institutes of Health-AARP Diet and Health Study. Thyroid 21, 957-963 (2011)
22. C.H. Tseng, Thyroid cancer risk Is not Increased in diabetic patients. PLoS One 7, e53096 (2012)
23. D.M. Freedman, A.C. Looker, C.C. Abnet, M.S. Linet, B.I. Graubard, Serum 25-hydroxyvitamin D and cancer mortality in the NHANES III study (1988-2006). Cancer Res. 70, 8587-8597 (2010)
24. D.M. Freedman, A.C. Looker, S.C. Chang, B.I. Graubard, Prospective study of serum vitamin D and cancer mortalityin the United States. Natl. Cancer Inst. 7, 1594-1602 (2007)
25. E. Giovannucci, Epidemiological evidence for vitamin D and colorectal cancer. J. Bone Miner. Res. 22, V81-V85 (2007)
26. E. Giovannucci, Vitamin D status and cancer incidence and mortality. Adv. Exp. Med. Biol. 624, 31-42 (2008)
27. D. Macejova, S. Ondkova, J. Brtko, Vitamin D(3) affects expression of thyroid hormone receptor alpha and deiodinase activity in liver of MNU-treated Sprague-Dawley rats. Gen. Physiol. Biophys. 28, 363-370 (2009)
28. J. Köhrle, Thyroid hormone transporters in health and disease: advances in thyroid hormone deiodination. Best Pract. Res. Clin. Endocrinol. Metab. 21, 173-191 (2007)
29. J. Köhrle, Local activation and inactivation of thyroid hormones: the deiodinase family. Mol. Cell. Endocrinol. 151, 103-119 (1999)
30. E.A. Platz, A.M. De Marzo, Epidemiology of inflammation and prostate cancer. J. Urol. 171, 36-40 (2004)
31. G. Vitale, M.P. Brugts, G. Ogliari, D. Castaldi, L.M. Fatti, A.J. Varewijck, S.W. Lamberts, D. Monti, L. Bucci, E. Cevenini, F. Cavagnini, C. Franceschi, L.J. Hofland, D. Mari, J. Janssen, Low circulating IGF-I bioactivity is associated with human longevity: Findings in centenarians' offspring. Aging (Albany NY) 4, 580-589 (2012)
32. P. Vigneri, F. Frasca, L. Sciacca, G. Pandini, R. Vigneri, Diabetes and cancer. Endocr. Relat. Cancer 16, 1103-1123 (2009)
33. Y.J. Liu, W. Qiang, J. Shi, S.Q. Lv, M.J. Ji, B.Y. Shi, Expression and significance of IGF-1 and IGF-1R in thyroid nodules. Endocrine (2013). doi: 10.1007/s12020-012-9864-z